Neoantigen quality predicts immunoediting in survivors of pancreatic cancer

To establish the edited neoantigens, we prolonged our earlier neoantigen high quality mannequin^4,5 that quantifies the immunogenic options of a neoantigen to suggest that two competing outcomes decide whether or not a neoantigen is high-quality—whether or not the immune system acknowledges or tolerates a neoantigenic mutation (Fig. 3a). To estimate the probability the immune system acknowledges a neoantigen, we measure the sequence similarity of the mutant neopeptide (p^MT) to identified immunogenic antigens. This infers the ‘non-self’ recognition potential R of p^MT, a proxy for peptides throughout the recognition house of the T cell receptor (TCR) repertoire.

Comments

0 comments